title: Purinergic modulation of field stimulation responses of rat and human vas deferens smooth muscle.
abstract: 1. Guanethidine at 5 x 10(-6) M strongly inhibited rat prostatic but not epididymal vas deferens, reflecting differences in innervation and the neurogenic field stimulation responses of these tissues. 2. Adenosine and ATP inhibited the field stimulation responses of rat prostatic vas deferens by 56 and 50% respectively. A 10-min pretreatment with 10(-4) M caffeine partly reversed this inhibition, by 55% in the case of adenosine and 60% for ATP. 3. Pretreatment for 10 min with 5 microM quinidine failed to significantly alter the extent of either adenosine or ATP inhibition of the field stimulation responses of rat prostatic vas deferens. 4. 8-Phenyltheophylline, the selective blocker of the A1 subtype of the P1 receptor, partly reversed adenosine-induced inhibition of the vas deferens FS responses. NECA, the selective agonist of the A2 subtype of the P1 receptor, very strongly inhibited vas deferens FS responses. 5. Field stimulation responses of human vas deferens were also inhibited by both adenosine and ATP but to a lesser extent and more variably than in rat tissue. 6. Adenosine and ATP inhibition was reversed by caffeine pretreatment, but far more variably than in rat tissue, and quinidine was without significant effect on inhibition of the responses. 7. It is concluded that in these tissues adenosine and ATP may operate via a P1 type receptor of both A1 and A2 subtypes and that a P2 type receptor may be lacking.
authors.affiliation: Division of Biological Sciences, Lancaster University, England.
authors.forename: M
authors.initials: M
authors.lastname: Lynch
authors.forename: H
authors.initials: H
authors.lastname: Huddart
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D004558:Electric Stimulation; D006145:Guanethidine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D011802:Quinidine / Q000494:pharmacology; D051381:Rats; D011983:Receptors, Purinergic / Q000502:physiology*; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D001743:Urinary Bladder / Q000187:drug effects / Q000502:physiology; D014649:Vas Deferens / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D011983:Receptors, Purinergic; D014665:Vasodilator Agents; D019830:Adenosine-5'-(N-ethylcarboxamide); D002110:Caffeine; D000255:Adenosine Triphosphate; D013806:Theophylline; C028322:8-phenyltheophylline; D011802:Quinidine; D000241:Adenosine; D006145:Guanethidine